Cargando…

Diagnostic potential of circulating LncRNAs in human cardiovascular disease: a meta-analysis

Cardiovascular disease (CVD) is a major killer of the human population around the world. Identifying effective diagnostic biomarkers for CVDs is particularly important in order to guide optimizing treatment. Accumulating evidence on aberrantly regulated circulating long non-coding RNAs (LncRNAs) pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Fei, Wang, Tao, Zeng, Lini, Zhu, Shanshan, Cao, Wenjun, Wu, Wei, Wu, Hongfu, Zou, Tangbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435511/
https://www.ncbi.nlm.nih.gov/pubmed/30361292
http://dx.doi.org/10.1042/BSR20181610
_version_ 1783406647082745856
author Luo, Fei
Wang, Tao
Zeng, Lini
Zhu, Shanshan
Cao, Wenjun
Wu, Wei
Wu, Hongfu
Zou, Tangbin
author_facet Luo, Fei
Wang, Tao
Zeng, Lini
Zhu, Shanshan
Cao, Wenjun
Wu, Wei
Wu, Hongfu
Zou, Tangbin
author_sort Luo, Fei
collection PubMed
description Cardiovascular disease (CVD) is a major killer of the human population around the world. Identifying effective diagnostic biomarkers for CVDs is particularly important in order to guide optimizing treatment. Accumulating evidence on aberrantly regulated circulating long non-coding RNAs (LncRNAs) promise to serve as a diagnostic or prognostic biomarker for various types of CVDs. We summarized studies to identify the potential diagnostic values of LncRNAs in CVD patients. We included articles reporting on the association between LncRNAs and diagnosis in CVDs. We calculated sensitivities, specificities, and area under the curves of LncRNAs. The pooled overall sensitivity and specificity for LncRNAs expression profile in differentiating CVD patients from controls (non-CVDs or healthy subjects) were 0.74 (95%CI 0.68–0.80) and 0.81 (95%CI 0.76–0.85), respectively; the overall positive likelihood ratio, 3.9 (95%CI 3.1–4.9); the negative likelihood ratio, 0.32 (95%CI 0.25–0.40); corresponding to an area under curve of 0.85 (95%CI 0.82–0.88) and overall diagnostic odds ratio 12 (95%CI 9–18). Subgroup analysis showed that the detection of LncRNAs expression in plasma substantially improved the diagnostic accuracy. Likewise, meta-regression analysis indicated that the detection method and sample size were the main source of heterogeneity. All these results suggested a relatively good reference value of LncRNAs as auxiliary biomarkers for CVDs, and should be considered in cases where the diagnosis is uncertain. Population-based prospective cohort studies are warranted to confirm our findings.
format Online
Article
Text
id pubmed-6435511
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-64355112019-04-12 Diagnostic potential of circulating LncRNAs in human cardiovascular disease: a meta-analysis Luo, Fei Wang, Tao Zeng, Lini Zhu, Shanshan Cao, Wenjun Wu, Wei Wu, Hongfu Zou, Tangbin Biosci Rep Research Articles Cardiovascular disease (CVD) is a major killer of the human population around the world. Identifying effective diagnostic biomarkers for CVDs is particularly important in order to guide optimizing treatment. Accumulating evidence on aberrantly regulated circulating long non-coding RNAs (LncRNAs) promise to serve as a diagnostic or prognostic biomarker for various types of CVDs. We summarized studies to identify the potential diagnostic values of LncRNAs in CVD patients. We included articles reporting on the association between LncRNAs and diagnosis in CVDs. We calculated sensitivities, specificities, and area under the curves of LncRNAs. The pooled overall sensitivity and specificity for LncRNAs expression profile in differentiating CVD patients from controls (non-CVDs or healthy subjects) were 0.74 (95%CI 0.68–0.80) and 0.81 (95%CI 0.76–0.85), respectively; the overall positive likelihood ratio, 3.9 (95%CI 3.1–4.9); the negative likelihood ratio, 0.32 (95%CI 0.25–0.40); corresponding to an area under curve of 0.85 (95%CI 0.82–0.88) and overall diagnostic odds ratio 12 (95%CI 9–18). Subgroup analysis showed that the detection of LncRNAs expression in plasma substantially improved the diagnostic accuracy. Likewise, meta-regression analysis indicated that the detection method and sample size were the main source of heterogeneity. All these results suggested a relatively good reference value of LncRNAs as auxiliary biomarkers for CVDs, and should be considered in cases where the diagnosis is uncertain. Population-based prospective cohort studies are warranted to confirm our findings. Portland Press Ltd. 2018-12-21 /pmc/articles/PMC6435511/ /pubmed/30361292 http://dx.doi.org/10.1042/BSR20181610 Text en © 2018 The Author(s). http://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Articles
Luo, Fei
Wang, Tao
Zeng, Lini
Zhu, Shanshan
Cao, Wenjun
Wu, Wei
Wu, Hongfu
Zou, Tangbin
Diagnostic potential of circulating LncRNAs in human cardiovascular disease: a meta-analysis
title Diagnostic potential of circulating LncRNAs in human cardiovascular disease: a meta-analysis
title_full Diagnostic potential of circulating LncRNAs in human cardiovascular disease: a meta-analysis
title_fullStr Diagnostic potential of circulating LncRNAs in human cardiovascular disease: a meta-analysis
title_full_unstemmed Diagnostic potential of circulating LncRNAs in human cardiovascular disease: a meta-analysis
title_short Diagnostic potential of circulating LncRNAs in human cardiovascular disease: a meta-analysis
title_sort diagnostic potential of circulating lncrnas in human cardiovascular disease: a meta-analysis
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435511/
https://www.ncbi.nlm.nih.gov/pubmed/30361292
http://dx.doi.org/10.1042/BSR20181610
work_keys_str_mv AT luofei diagnosticpotentialofcirculatinglncrnasinhumancardiovasculardiseaseametaanalysis
AT wangtao diagnosticpotentialofcirculatinglncrnasinhumancardiovasculardiseaseametaanalysis
AT zenglini diagnosticpotentialofcirculatinglncrnasinhumancardiovasculardiseaseametaanalysis
AT zhushanshan diagnosticpotentialofcirculatinglncrnasinhumancardiovasculardiseaseametaanalysis
AT caowenjun diagnosticpotentialofcirculatinglncrnasinhumancardiovasculardiseaseametaanalysis
AT wuwei diagnosticpotentialofcirculatinglncrnasinhumancardiovasculardiseaseametaanalysis
AT wuhongfu diagnosticpotentialofcirculatinglncrnasinhumancardiovasculardiseaseametaanalysis
AT zoutangbin diagnosticpotentialofcirculatinglncrnasinhumancardiovasculardiseaseametaanalysis